image
Healthcare - Biotechnology - NASDAQ - US
$ 3.29
3.13 %
$ 13.8 M
Market Cap
-2.74
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AIMD stock under the worst case scenario is HIDDEN Compared to the current market price of 3.29 USD, Ainos, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AIMD stock under the base case scenario is HIDDEN Compared to the current market price of 3.29 USD, Ainos, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AIMD stock under the best case scenario is HIDDEN Compared to the current market price of 3.29 USD, Ainos, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AIMD

image
$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5$0.0$0.020252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25
FINANCIALS
20.7 K REVENUE
-83.02%
-13.8 M OPERATING INCOME
-4.81%
-14.9 M NET INCOME
-7.93%
-5.81 M OPERATING CASH FLOW
-23.72%
-125 K INVESTING CASH FLOW
-23.41%
8.03 M FINANCING CASH FLOW
63.00%
106 K REVENUE
0.00%
-3.16 M OPERATING INCOME
31.74%
-3.29 M NET INCOME
29.39%
-1.22 M OPERATING CASH FLOW
-41.70%
-20.6 K INVESTING CASH FLOW
-154.96%
14.6 K FINANCING CASH FLOW
105.41%
Balance Sheet Ainos, Inc.
image
Current Assets 4.34 M
Cash & Short-Term Investments 3.89 M
Receivables 56
Other Current Assets 445 K
Non-Current Assets 24.5 M
Long-Term Investments 0
PP&E 560 K
Other Non-Current Assets 23.9 M
13.51 %83.01 %Total Assets$28.8m
Current Liabilities 3.95 M
Accounts Payable 0
Short-Term Debt 3 M
Other Current Liabilities 955 K
Non-Current Liabilities 9.35 M
Long-Term Debt 9 M
Other Non-Current Liabilities 349 K
22.55 %7.18 %67.65 %Total Liabilities$13.3m
EFFICIENCY
Earnings Waterfall Ainos, Inc.
image
Revenue 20.7 K
Cost Of Revenue 52.6 K
Gross Profit -31.9 K
Operating Expenses 13.8 M
Operating Income -13.8 M
Other Expenses 1.02 M
Net Income -14.9 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)21k(53k)(32k)(14m)(14m)(1m)(15m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-153.73% GROSS MARGIN
-153.73%
-66772.17% OPERATING MARGIN
-66772.17%
-71702.26% NET MARGIN
-71702.26%
-95.79% ROE
-95.79%
-51.57% ROA
-51.57%
-49.67% ROIC
-49.67%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ainos, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -14.9 M
Depreciation & Amortization 4.8 M
Capital Expenditures -21.3 K
Stock-Based Compensation 3.54 M
Change in Working Capital 37.1 K
Others 686 K
Free Cash Flow -5.83 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ainos, Inc.
image
AIMD has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Ainos, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
2.25 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Water Tower Research Spotlights Ainos' Advances and Milestones in Digital Olfaction and Healthcare: Entering Inflection Point in 2H25 Ainos Hits Inflection Point with AI Nose Pilot Ramp in Senior Care, Robotics, and Semiconductors Key VELDONA® Human Clinical Studies Secure Taiwan Regulatory Greenlight, Accelerating Development SAN DIEGO, CA / ACCESS Newswire / June 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' critical milestones and strategic advancements in 1H25, and its robust roadmap for the remainder of the year, with multiple large scale AI Nose pilot programs and Veldona ® clinical trials on deck. Key Highlights from the Report: Breakthroughs in accuracy and revenues demonstrate senior care market readiness: AI Nose achieved an 85% accuracy rate in hygiene monitoring, exceeding a performance target of 80%. accessnewswire.com - 1 month ago
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy AI Nose Platform Advances Toward Scaled Pilot Programs Across Healthcare, Robotics, and Industrials VELDONA® Oral Interferon Receives Approval to Begin Human Trials in Taiwan SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today issued a mid-year update outlining key strategic milestones achieved during the first half of 2025. The Company has transitioned from R&D to commercial execution, marked by its first AI Nose-driven revenue, expanded industry partnerships, and regulatory approval for its lead VELDONA human drug candidates to enter clinical trials. accessnewswire.com - 1 month ago
Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting a significant milestone in the Company's AI Nose project for elderly care. AI Nose has reached approximately 85% accuracy in excretion odor detection-improving over the recently met internal milestone of 80%. accessnewswire.com - 1 month ago
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80% Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors data, an improvement from 80% previously, based on collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for subsequent statistical evaluation. The milestone validates AI Nose as a deploy able solution for non-contact hygiene monitoring in long-term care (LTC) and positions Ainos to lead the emerging SmellTech category. accessnewswire.com - 1 month ago
Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner Robotic Smell Intelligence Goes Live at Asia's Premier AI Tech Stage SAN DIEGO, CA / ACCESS Newswire / May 22, 2025 / Ainos, Inc. (NASDAQ:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer in AI-driven scent digitization, announced the official debut of its proprietary AI Nose platform at COMPUTEX 2025, alongside ugo, Inc, Japan's top service robotics company. This milestone marks the first public demonstration of real-time robotic olfaction-a new sensory category poised to transform smart robotics, environmental AI, and safety infrastructure. accessnewswire.com - 1 month ago
Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy Early results show steroid-free remission, opening pathway into $13B global pet dental health market VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 19, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer of low-dose oral interferon therapeutics, today announced compelling interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis ("FCGS"), a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class of immunotherapy in companion animals. accessnewswire.com - 1 month ago
Water Tower Research Highlights Ainos' Significant Commercial Traction and Strategic Milestones Across Multiple Sectors 412% revenue growth reflects AI Nose sales in elderly care Expanding AI-driven scent tech beyond healthcare into robotics and industrial applications SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 14, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's significant progress in commercializing its AI-driven scent digitization platform, AI Nose, and expanding into multiple market verticals. Notably, Ainos has achieved a key milestone of achieving over 80% accuracy in its senior care project. accessnewswire.com - 2 months ago
Ainos Reports First Quarter 2025 Financial Results Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents a significant step forward in advancing our long-term strategy to build a differentiated healthcare and technology company powered by scent digitization, AI-enhanced diagnostics and innovative therapeutics. accessnewswire.com - 2 months ago
Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly Robotic smelltech by AI Nose moves from concept to integration in weeks Partnership fast-tracks robotic smell integration as global service robotics market nears $40.6B, Japan $1.2B SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's successful installation of its AI Nose technology onto a humanoid robot developed by ugo, Inc., Japan's leading service robot company. The milestone, achieved just weeks after announcing the partnership, demonstrates fast execution and marks a global first in robotic smell integration. accessnewswire.com - 2 months ago
Ainos and ugo Complete First Robotic Smell Integration in Japan Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed on April 9, 2025, the installation marks the world's first robot with a functional sense of smell, a breakthrough that redefines the frontier of robotics, AI, and human-machine interaction. accessnewswire.com - 2 months ago
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ("Ainos" or the "Company"), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study. accessnewswire.com - 3 months ago
Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling Strategic partnerships and industry-leading accuracy position Ainos as a game-changer in digitized scent technology SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 11, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting the Company's expansion of its AI Nose technology into the robotics and semiconductor sectors. The report features insights from a management fireside chat on April 8, 2025. accessnewswire.com - 3 months ago
8. Profile Summary

Ainos, Inc. AIMD

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 13.8 M
Dividend Yield 0.00%
Description Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Contact 8880 Rio San Diego Drive, San Diego, CA, 92108 https://ainos.com
IPO Date Jan. 8, 2021
Employees 44
Officers Mr. Chih-Heng Lu Director of Corporate Developoment Mr. Hsin-Liang Lee Chief Financial Officer Mr. Chun-Hsien Tsai Chief Executive Officer, President & Chairman of the Board